Phase I Study of Pazopanib Alone & In Combination With Lapatinib in

See also
Status	Clinical Trial	Phase
Completed	`NCT02248389` - Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses	Phase 1
Completed	`NCT03900364` - a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy	N/A
Completed	`NCT00158782` - Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients	Phase 1
Completed	`NCT03109015` - Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing	Phase 2
Completed	`NCT00363194` - A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients	Phase 1
Completed	`NCT01012011` - Regulatory Post Marketing Surveillance Study on Nexavar®	N/A
Completed	`NCT00842790` - Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging	N/A
Completed	`NCT00529802` - Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer	Phase 2
Completed	`NCT00356460` - Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma	Phase 1
Completed	`NCT00338884` - Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer	Phase 2
Completed	`NCT00387764` - Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer	Phase 3
Completed	`NCT00095186` - Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma	Phase 2
Completed	`NCT00079612` - Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer	Phase 2
Completed	`NCT00043368` - PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)	Phase 2
Active, not recruiting	`NCT04489771` - A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)	Phase 2
Withdrawn	`NCT05104905` - A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma	Phase 1/Phase 2
Terminated	`NCT03685591` - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors	Phase 1
Withdrawn	`NCT03111901` - Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer	Phase 1/Phase 2
Recruiting	`NCT05544929` - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers	Phase 1
Completed	`NCT02917772` - Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma	Phase 2

NCT number	NCT00516672
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 1
Start date	September 10, 2007
Completion date	October 14, 2015

Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms